期刊文献+

氟尿嘧啶类药物的性味辨析初探 被引量:9

Nature and flavor of 5-fluorouracil: a TCM perspective
下载PDF
导出
摘要 通过辨析化疗药物的性味,有望让化疗药物与中医体系融合并丰富中药学的内容,也可能为个体化应用化疗药物提供新的思路。我们据中医理论及氟尿嘧啶类药物在人体的反应,通过辨析和口尝,结合当前中药减毒领域内的新成果,确认氟尿嘧啶类药物为苦、辛,大热,有毒之品。未来的研究需要观察虚寒体质和阳热体质的患者在疗效和副作用上可能存在的不同。 By analyzing the properties (nature and ftavour) of chemotherapy drugs from a perspective of traditional Chinese medicine (TCM), this article aims to integrate chemotherapy drugs with the TCM system and expects to enrich the content of Chinese Herbology and provide new ideas for individualized application of chemotherapy drugs as well. On the basis of TCM theory and the responses of 5-fluorouracil in human, we analyzed and tasted 5-fluorouracil in consideration of the current achievements in the field of toxicity reduction of Chinese herbs, and recognized that 5-ftuorouracil is bitter and pungent in flavor, hot and toxic in nature. Our future study will focus on observing the possible differences in efficacy and side-effect in patients with asthenia cold syndromes and those presenting Yang-heat syndromes.
出处 《医学争鸣》 CAS 北大核心 2013年第4期33-35,共3页 Negative
基金 陕西省中医药管理局资助项目(LC79)
关键词 氟尿嘧啶 性味 辨析 5-fluorouracil nature and flavor differentiation
  • 相关文献

参考文献14

  • 1van Wietmarschen H, Yuan K, Lu C, et al. Systems biology guided by chinese medicine reveals new markers for sub- typing rheumatoid arthritis patients[J]. J Clin Rheumatol, 2009, 15(7):330-337.
  • 2Moertel CG. Chemotherapy for colorectal cancer[J]. N Engl J Med, 1994, 330(16):1136-1142.
  • 3Stein BN, Petrelli N J, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase iii trial[J]. Cancer, 1995, 75(1): 11-17.
  • 4de Gramont A, Figer A, Seymour M, et al. Leucovorin and fiuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
  • 5Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22(1):23-30.
  • 6Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil?[J]. Clin Pharmacokinet, 1999, 36(6):391-398.
  • 7Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised?[J]. Clin Pharmacokinet, 2006, 45(6):567-592.
  • 8Highlights from: 5-fluorouracil drug management pharmacokinetics and pharmacogenomics workshop[J]. Clin Colorectal Cancer, 2007, 6(6):407-422.
  • 9Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a muhicenter randomized trial of patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(13):2099-2105.
  • 10Yang CG, Ciccolini J, Blesius A, et al. Dpd-based adaptive dosing of 5-fu in patients with head and neck cancer: impact on treatment efficacy and toxicity[J]. Cancer Chemother Pharmacol, 2011, 67(1):49-56.

共引文献21

同被引文献155

引证文献9

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部